Genetics, Screening & Emerging-Technology Ethics

Skip anything

Every question is optional. No one has to retell painful events, name a diagnosis, or choose a religion or identity to begin.

Pause or stop

Stop at any point. Nothing is sent anywhere, and nothing is shared unless the person chooses it in the sharing review.

Whose words

Record who said each thing: the person, a caregiver or surrogate, or a professional. A caregiver's needs get their own field.

Support to take part

Extra time, a quieter place, pictures, an interpreter or a trusted person can help someone say what matters. Ask what helps.

Barriers are not preferences

Cost, travel, work, housing, caring for others and digital access are written down as barriers, not as what the person wants.

Meaning, religious or not

Hope, purpose, faith, relationships and identity can be part of the conversation if the person wants. None is assumed.

• Genetic counselor: Test options, what results can and cannot show, and family implications.
• Physician: Whether testing changes care.
• Psychologist or social worker: Support with results and family conversations.
• Chaplain or spiritual-care provider: Meaning, distress, hope and relationships, for people of any faith or none.
• Interpreter or communication specialist: Language and communication support so the person's own words come through.
• People the person chooses: Family, friends, or a community or faith contact, only if the person wants them. Never assumed safe, available or wanted.

Roles, titles and training differ by country and service. Not every role exists everywhere.

A small set of places chosen for contrast, not a ranking or a representative survey: Global, Saudi Arabia, Multi-country, Asian setting, Germany, Australia, Brazil, United States. Each example states what its source establishes and what it does not. Policy on paper is not proof that a service is available.

Guidance, not outcomes:

Shows what is written or recommended. It does not show that it is followed or what results.

Abstract only:

Read from the abstract. The full paper may add or qualify this.

Service as described:

Describes a service when the source was written. Whether it still runs is not verified.

Place from authors:

The place is taken from the authors' affiliations, not from where data were collected.

Policy, not outcomes:

Shows what is written or recommended. It does not show that it is followed or what results.

Availability not verified:

Whether this is available today was not checked.

• Global · Guidance · 2024

  WHO 2024 guidance on human genome data says informed consent should be as specific and granular as possible about potential uses, including use by for-profit entities and sharing data to train artificial intelligence.

  Limits: Guidance, not outcomes

  What others could learn: A genomic consent conversation can name concrete uses people may not expect, such as commercial reuse and training AI, and say where data are held, who reviews access and what withdrawal can and cannot undo.

  Conditions, limits and source

  Conditions that matter:

  Needs a governance body that reviews access requests, a working withdrawal mechanism, and consent materials tailored to social and cultural context, as the guidance itself states.

  Cannot be inferred:

  Does not show how any country or biobank applies these principles, or that granular consent improves understanding or trust. Not binding law. Says nothing on what a clinician should disclose in routine testing.

  Limits:

  Normative principles, not an evaluation. The same section allows broad consent where no specific purpose can be named, if safeguards such as a data access committee apply, and notes that the right to withdraw can have justified limits. It names the right not to know only for children's data.

  Source: World Health Organization, Guidance for human genome data collection, access, use and sharing (Section 3.1 recommendations, printed p. 5 (PDF p. 15)). Where: Global. Population: People whose genome data are collected, accessed, used or shared, with attention to families and communities. Published 2024-11-17; retrieved 2026-10-11.

• Global · Guidance · 2021

  WHO 2021 guidance on AI for health says physicians should tell patients when AI is used rather than hide it, and should explain its purpose, how it functions and whether it is explainable.

  Limits: Guidance, not outcomes

  What others could learn: A care team can say whether software helped interpret a result or shape a recommendation, what data it used, and what its known weaknesses are. Patients can then weigh that alongside the clinician's view.

  Conditions, limits and source

  Conditions that matter:

  Needs clinicians who understand the tool well enough to explain it, vendor documentation on training data and limits, and an institutional policy on when disclosure is expected.

  Cannot be inferred:

  Does not show that disclosure changes patient trust, decisions or outcomes. Does not establish a legal duty to disclose in any country. Does not describe any genomic interpretation tool.

  Limits:

  Normative guidance in an ethics box. The same section says providers are unlikely to inform patients that AI informed a decision and that there is no precedent for seeking consent to use diagnostic technologies. It poses disclosure duties as open questions. It is not specific to genetics.

  Source: World Health Organization, Ethics and governance of artificial intelligence for health: WHO guidance (Box 4 'Informed consent during clinical care', section 6, printed p. 48 (PDF p. 64)). Where: Global. Population: Patients whose care involves AI-guided recommendations, and their physicians. Published 2021-06-25; retrieved 2026-10-11.

• Saudi Arabia · Measured outcome · 2012

  A Saudi Ministry of Health records study of compulsory premarital screening for sickle cell disease and beta-thalassemia found couples cited uncancellable wedding plans and fear of social stigma as reasons for proceeding with marriage.

  Limits: Abstract only · Service as described

  What others could learn: Timing and social pressure may limit what a result can change. About half the couples thought screening best before engagement and wedding plans, and counseling showed no difference in marriage decisions. A program could test whether earlier results and support for family pressure widen couples' real choices.

  Conditions, limits and source

  Conditions that matter:

  A compulsory national screening program with Ministry of Health records. Counseling capacity was a stated gap, since most couples received no advice to attend genetic counseling.

  Cannot be inferred:

  Does not show how couples decide today, how the program currently works, or how couples elsewhere would respond. Does not show that marrying or not marrying was the right or wrong decision. Not a basis for judging any community.

  Limits:

  Abstract only. The abstract reports 824 of 934 at-risk couples (88.2%) married. The case-control comparison used couples reachable by the study. Data are from 2005-2006, and program rules and counseling practice may have changed since.

  Source: Journal of Genetic Counseling (Ministry of Health, Riyadh, author affiliation), At-risk marriages after compulsory premarital testing and counseling for β-thalassemia and sickle cell disease in Saudi Arabia, 2005-2006 (Abstract (PubMed PMID 21826578)). Where: Saudi Arabia. Population: Couples identified as at risk of having children with sickle cell disease or beta-thalassemia through the national premarital screening program, 2005-2006. Published 2012-04; retrieved 2026-10-11.

• Multi-country · Service described in 2016

  An analysis of H3Africa consent documents found that of 13 projects, six did not mention returning individual genetic research results and five stated none would be returned.

  What others could learn: Consent forms for biobank or research projects can state plainly whether individual results will be returned. People who want to know, or not know, can then ask about it before they join.

  Conditions, limits and source

  Conditions that matter:

  Requires a decision by the project and its ethics committee on return of results, access to a clinical facility to verify findings, and genetic counselors. Only one project described verified feedback by a study doctor and a genetic counselor.

  Cannot be inferred:

  Does not show current H3Africa practice, what participants wanted, or any national policy. Research consent is not the same as clinical genetic testing.

  Limits:

  Analyzes written documents in English and French, not translations, what participants understood or what they were told in person. Six of 19 projects' documents were not analyzed. Of 13 projects, seven used broad consent, five tiered and one specific.

  Source: Journal of Medical Ethics (BMJ), Obtaining informed consent for genomics research in Africa: analysis of H3Africa consent documents (Results, 'Feedback of genetic and non-genetic results' (PMC4752624); also stated in the abstract). Where: Multi-country (African H3Africa consortium projects). Population: Research participants in genomics and biobanking projects of the Human Heredity and Health in Africa (H3Africa) Consortium. Published 2016-02; retrieved 2026-10-11.

• Asian setting · Reported experience · 2018

  In interviews with 24 women who received hereditary cancer genetic test results in an Asian setting (authors based in Singapore), barriers to sharing negative or uncertain results were perceiving no implication for relatives and result ambiguity.

  Limits: Abstract only · Place from authors

  What others could learn: After a negative or uncertain result, a counselor can say plainly whether the result matters for relatives and write that into the report. Family-facing wording then does not rest on the patient's own reading.

  Conditions, limits and source

  Conditions that matter:

  Needs counselor time after results, plain-language letters for relatives, and a clear classification of results. The abstract names family closeness and family involvement in testing as facilitators for all result types.

  Cannot be inferred:

  Does not describe family communication in any one country or across Asia, nor any ethnic or religious group. Not representative of men or of people without cancer histories.

  Limits:

  Abstract only. Small sample from one service. The abstract does not name the country. The authors state facilitators and barriers are similar to those among Western women.

  Source: Psycho-Oncology (journal); National Cancer Centre Singapore (author affiliation), Factors influencing the decision to share cancer genetic results among family members: An in-depth interview study of women in an Asian setting (Abstract, results (PubMed PMID 29314485)). Where: Asian setting (not named in the abstract; authors are affiliated with Singapore institutions). Population: 24 women with a personal or family history of breast or ovarian cancer who received a positive, negative or uncertain genetic test result. Published 2018-03; retrieved 2026-10-11.

• Germany · Policy · 2024

  A 2024 legal literature review of German law says the Genetic Diagnostics Act points counselors to advise the patient, and whether "necessity as justification" permits breaching confidentiality to inform at-risk relatives remains legally unclear.

  Limits: Abstract only · Policy, not outcomes · Availability not verified

  What others could learn: Where the law leaves relative notification unsettled, the practical step is to settle it before testing. A counselor can ask who the patient wants told, document that, and give the patient material to pass to relatives.

  Conditions, limits and source

  Conditions that matter:

  Needs counselors who know the confidentiality rules in their jurisdiction, a documented pre-test discussion of sharing, and written family-facing information.

  Cannot be inferred:

  Does not describe how often relatives are told or what German courts decided. Does not cover the Act's provisions on the right not to know. Not legal advice, and other countries' rules differ, as the authors note.

  Limits:

  Abstract only. A secondary legal analysis, not the statute text. The statute host (gesetze-im-internet.de) was blocked. The abstract says that for avoidable or treatable disorders, geneticists should confine themselves to advising the patient.

  Source: Journal of Medical Ethics (BMJ), Rights and duties of genetic counsellors in Germany related to relatives at risk: comparative thoughts on the German Genetic Diagnostics Act (Abstract (PubMed PMID 37451858)). Where: Germany. Population: Patients undergoing genetic testing, their at-risk relatives and genetic counselors. Published 2024-05-09; retrieved 2026-10-11.

• Australia · Measured outcome · 2024

  In an Australian online survey of 367 people offered clinical genetic testing (89% already tested), discrimination concerns still affected some decisions despite the 2019 partial industry moratorium on genetic results in life insurance; 16% knew of it.

  Limits: Service as described

  What others could learn: Before testing, a clinician can ask what a patient knows about insurance rules, say that rules differ by place and time, and point to a current official source. Many respondents here did not know the rules then in force.

  Conditions, limits and source

  Conditions that matter:

  Depends on a legal or industry framework for genetic results in insurance. In Australia the moratorium was a voluntary industry measure, and respondents mostly favored government legislation.

  Cannot be inferred:

  Does not show how many Australians avoid testing, or that the moratorium causes or prevents avoidance. Describes rules as of 2021 to 2022 only. Not comparable to other countries' laws.

  Limits:

  Convenience sample recruited via patient groups, social media and snowballing; the authors note responder bias. 89% had been tested and 76% of those had a positive result. Item denominators vary (16% is 54 of 340). The moratorium was industry-led and partial, with limits on cover amounts. The paper reports the industry body planned to make it indefinite from 2023, and secondary sources report Australia has since legislated against use of genetic results in life insurance; verify the current Act. The survey predates both.

  Source: European Journal of Human Genetics, Community concerns about genetic discrimination in life insurance persist in Australia: A survey of consumers offered genetic testing (Abstract (PubMed PMID 37169978); recruitment dates in Methods (PMC10923945)). Where: Australia. Population: Australian consumers who had taken or been offered clinical genetic testing for adult-onset conditions. Published 2024-03; retrieved 2026-10-11.

• Brazil · Measured outcome · 2026

  In a survey of 207 Brazilian breast cancer patients reached through advocacy groups, 89% of 181 respondents rated their own pre-diagnosis awareness of genetic testing as moderate to very low; cost and limited awareness were prominent barriers.

  Limits: Availability not verified

  What others could learn: Where testing sits behind private coverage, a clinic could ask early what a patient knows about testing, whether cost and reimbursement are clear, and who will explain results. In this self-selected group, those counseled mostly found it helpful (89.3%) and almost none regretted testing (98.7%).

  Conditions, limits and source

  Conditions that matter:

  The authors state the public system (SUS) has no reimbursement code for breast cancer genetic testing and offers it mainly through research-linked tertiary centers. In the private sector, coverage rules exist but are hindered by bureaucracy, such as a requirement that a medical geneticist request the test. They also cite a shortage of medical geneticists and the role of oncologists and surgeons in referral. Higher income and age under 50 were independently linked to being tested.

  Cannot be inferred:

  Not representative of Brazilian breast cancer patients and likely overstates access. Does not show current coverage rules or service availability, and says nothing about consent procedures or how results are returned.

  Limits:

  Convenience sample reached through advocacy networks: respondents were younger, more educated and higher income than the Brazilian population, and the authors say the results should not be generalized. Self-reported testing status and experiences. The questionnaire was not validated for the Brazilian context and did not separate public from private care. The survey did not link surgical changes to test results. Survey items are not reproduced here. Published online January 2026 in a 2025 volume.

  Source: Frontiers in Oncology (Scarelli E, Teixeira CM, Viana E Silva N, et al.); PMC open access, Impact of breast cancer genetic testing in Brazilian patients: insights from the MAGENTA study (Results 3.2 (awareness levels, Table 2); abstract Results). Where: Brazil. Population: Women with breast cancer who answered an open online survey (n=207; median age 40; mostly highly educated); 81.6% had been tested and 60.4% had received genetic counseling. Published 2026-01-21; retrieved 2026-10-11.

• United States · Measured outcome · 2025

  In a single-arm US pilot, 55 of 148 approached patients in genetic counseling for inherited cancer risk enrolled, and 44% of 101 named relatives agreed to counselor contact; acceptability was high and no harms were reported.

  Limits: Service as described

  What others could learn: Before testing, a team could ask a patient whether the clinic may contact named relatives directly if a result matters for them, and record each relative's consent separately. The program was designed to complement, not replace, the patient's own conversations with family.

  Conditions, limits and source

  Conditions that matter:

  A genetic counselor delivered pre-test counseling, contacted consenting relatives by phone and returned results; relatives consented before the proband's result was known. Negative results were mailed and variants of uncertain significance were returned by phone. In the US, probands are usually expected to notify relatives themselves.

  Cannot be inferred:

  Does not show that direct contact increases testing or that it fits other privacy rules or health systems. Not representative of US patients, and the many probands who declined were not studied in depth.

  Limits:

  Pilot without a comparison group, so it cannot show that direct contact raises testing in relatives. One health system; English-speaking adults only. Only 37% of approached probands enrolled and 44% of named relatives consented. Few relatives had pathogenic findings, and 4 of 8 such relatives completed the follow-up survey. Survey measures are not reproduced here.

  Source: Public Health Genomics (Henrikson NB, Scrol A, Zepp JM, et al.); abstract via PubMed, full text via PMC, Health System-Led Early Consent and Direct Contact of At-Risk Relatives: Pilot Study Results (Abstract, Results). Where: United States (one integrated health system, Pacific Northwest). Population: Adult patients (probands) in genetic counseling for hereditary breast, ovarian or Lynch syndrome risk, and their first- and second-degree relatives (45 consenting relatives). Published 2025-04-03; retrieved 2026-10-11.

• The sourced examples include guidance, measured outcome, service description, reported experience, policy. Each quote was matched to the source text; that is not independent expert review.
• The prompts and fictional case are original. They have not been tested with patients, caregivers or clinicians.
• Whether this workflow helps anyone is an open research question.
• Content is in English. Interface translations are not reviewed for this topic.